Cytokinetics, Incorporated (CYTK)

NMS – Real Time Price. Currency in USD

82.19

+1.39 (1.72%)

At close: Jun 26, 2026, 4:00 PM EDT

82.46

+0.27 (0.33%)

After-hours: Jun 26, 2026, 7:42 PM EDT

09.06.2026

Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

08.06.2026

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program.

04.06.2026

Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?

01.06.2026

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

27.05.2026

Cytokinetics to Participate in June Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in June:

27.05.2026

Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript

22.05.2026

Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise

Cytokinetics NASDAQ: CYTK executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug's label, REMS program and recent clinical data in hypertrophic cardiomyopathy during a discussion hosted by RBC Capital Markets.

Videos

28.10.2025

Positive

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
CYTK	Raymond James	Market Perform	undefined >> undefined	July 30th 2025

Press releases

08.06.2026

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

01.06.2026

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

20.05.2026

Cytokinetics to Hold Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026 at 10:00 AM Pacific Time at the Company's headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics' performance.

18.05.2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2026 it granted stock options to purchase an aggregate of 20,807 shares of common stock and 13,793 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 8 employees, whose employment commenced in April and May 2026 as a material inducement to their employment.

Cytokinetics, Incorporated (CYTK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cytokinetics, Incorporated (CYTK)

Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics to Participate in June Investor Conferences

Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript